Hogehilweg 18 Mon-Fri 08:30-17:30
Mijn Medicijn
πŸ“ž Contact phone β€” free, 24/7

Order Omeprazole safely online in the Netherlands

★★★★☆ 4.5 (289 reviews)
In stock β€” ready for delivery today
Choose dosage and pack size
Package Price per Dose Price
360 pills €0,97
€435,08
€348,06
Free shipping
180 pills €1,10
€247,80
€198,24
Free shipping
120 pills €1,26
€189,15
€151,32
90 pills €1,39
€157,00
€125,60
60 pills €1,54
€115,38
€92,30
30 pills €1,86
€69,98
€55,98
10 pills €2,27
€28,36
€22,69
180 pills €1,09
€245,91
€196,73
Free shipping
120 pills €1,20
€179,70
€143,76
90 pills €1,33
€149,43
€119,54
60 pills €1,36
€102,13
€81,71
30 pills €1,66
€62,41
€49,93
360 pills €1,54
€692,36
€553,89
Free shipping
180 pills €1,62
€365,09
€292,07
Free shipping
120 pills €1,82
€272,39
€217,91
Free shipping
90 pills €2,03
€228,88
€183,10
Free shipping
60 pills €2,09
€157,00
€125,60
30 pills €2,60
€98,35
€78,68
€348,06
Quantity:
✈️
Airmail 14–21 days
⚑
Express delivery 5–9 days
🎁
Free Airmail from €182,34
πŸ”’
Crypto discount βˆ’10%

What Omeprazole is (brief)

Omeprazole is a proton pump inhibitor (PPI) that inhibits the H+/K+-ATPase enzyme in gastric parietal cells, thereby suppressing gastric acid secretion; its primary therapeutic use is in the management of gastroesophageal reflux disease and peptic ulcers.

Pharmacologically, it is a prodrug activated in the acidic secretory canaliculi of parietal cells, where it covalently binds to the proton pump and yields a sustained antisecretory effect that persists until new pumps are synthesized. Its antisecretory action is relatively independent of meal timing and typically requires several days for maximal healing of erosive disease.

Clinically available in enteric-coated oral formulations, omeprazole is used for short- or moderate-term therapy of acid-related disorders with dosing guided by indication, severity, and response. It is often administered once daily, with adjustments based on therapeutic goals and tolerability.

What it is used for (moderate)

Indications include gastroesophageal reflux disease (GERD) with or without erosive esophagitis, healing of erosive esophagitis, and maintenance therapy to prevent relapse. It is effective in promoting healing of duodenal and gastric ulcers and in managing peptic ulcer disease associated with Helicobacter pylori infection as part of combination regimens.

Omeprazole is also employed in healing and preventing ulcers linked to NSAID therapy, and in the management of pathological hypersecretion states such as Zollinger-Ellison syndrome. In selected regimens, it is used as part of triple or quadruple therapy for H. pylori eradication, alongside antibiotics and sometimes bismuth salts, to reduce gastric acidity and enhance antimicrobial activity.

In pediatric practice, approved dosing exists for certain ages and weight bands; however, long-term safety data in very young patients are more limited, and therapy is typically tailored to the clinical indication and response with careful monitoring for adverse effects. Antacid therapy may be used as adjunctive treatment in selected cases but does not replace antisecretory therapy for established erosive disease.

Contraindications and precautions (detailed β€” this is the focus)

Contraindications include known hypersensitivity to omeprazole or to other benzimidazole derivatives. If a patient has a history of severe immediate-type hypersensitivity to PPIs or related agents, alternative therapies should be considered and any prior reaction should be documented and monitored for recurrence.

Precautions in hepatic impairment are warranted; patients with mild to moderate hepatic disease generally require no baseline dose adjustment, but severe hepatic impairment necessitates careful titration and monitoring due to altered pharmacokinetics and potential accumulation. Prolonged use requires assessment of liver function in the setting of transaminase elevations or clinical signs suggestive of hepatotoxicity.

Magnesium deficiency has been reported with long-term PPI use, sometimes after several months; clinicians should monitor serum magnesium in at-risk patients or those on concomitant magnesium-wasting drugs. Vitamin B12 deficiency can occur with extended therapy due to reduced dietary B12 absorption, particularly in older adults or those with preexisting nutritional deficits; periodic assessment may be prudent during long courses.

Long-term PPI therapy may be associated with an increased risk of enteric infections (eg, Clostridioides difficile), community-acquired pneumonia, and bone fractures in populations at risk for osteoporosis. Rebound acid hypersecretion upon abrupt withdrawal can complicate discontinuation, necessitating a gradual taper or alternative strategies to minimize symptoms. Gastric malignancy should be considered and investigated if symptoms persist or worsen despite therapy, as antisecretory treatment does not exclude underlying malignancy.

Side effects by frequency (detailed)

Common adverse effects (occurring in roughly 1% to less than 10% of patients) include headache, abdominal pain, nausea, vomiting, diarrhea, flatulence, and dizziness. These events are usually mild and resolve with continued therapy or dose adjustment.

Uncommon adverse effects (approximately 0.1% to 1%) encompass skin rash, pruritus, dry mouth, and blurred vision. Less frequently, patients may report fatigue, back pain, nasal congestion, or edema; most reactions are nonserious and reversible with dose modification or discontinuation.

Rare adverse effects (<0.1%) include liver biochemical abnormalities, cholestatic or hepatocellular injury, pancreatitis, hypersensitivity reactions, and severe cutaneous adverse reactions such as Stevens-Johnson syndrome. Hematologic abnormalities, including thrombocytopenia or pancytopenia, have been reported rarely. Hyperglycemia or lactic acidosis is exceptionally uncommon and typically associated with other comorbidities.

Long-term therapy carries specific risks such as hypomagnesemia, vitamin B12 deficiency, nephritis, and enteric infections; there is also concern for increased fracture risk in susceptible individuals. Clinicians should counsel patients to report unusual diarrhea, persistent vomiting, seizure activity, or any signs of liver dysfunction promptly, especially during prolonged courses.

Interactions with other substances (detailed)

Clopidogrel is a notable interaction, as omeprazole inhibits the CYP2C19 pathway necessary for optimal clopidogrel activation. Clinically, this may attenuate antiplatelet efficacy and potentially increase thrombotic risk; alternative PPIs with less CYP2C19 inhibition or close monitoring may be considered in high-risk patients.

Drugs dependent on gastric acidity for absorptionβ€”such as ketoconazole, itraconazole, and atazanavirβ€”may have reduced bioavailability when coadministered with omeprazole. Iron salts and calcium carbonate may also have diminished absorption; spacing separate dosing by several hours is commonly advised when concomitant administration is necessary.

CYP2C19 and related metabolic interactions include increased plasma concentrations of diazepam, phenytoin, and sometimes warfarin, necessitating careful monitoring and possible dose adjustments of these agents when used with omeprazole.

Antiretroviral and antifungal agents with pH-dependent absorption, such as voriconazole and certain protease inhibitors, may exhibit decreased absorption with concomitant omeprazole therapy; alternative regimens or timing strategies should be considered. Additionally, high-dose methotrexate, digoxin, or certain risedronate/alendronate regimens may have altered pharmacodynamics or absorption; clinicians should review concomitant therapies and adjust timing to minimize interactions.

✈️

Airmail

14–21 days. Free from €182,34 .

⚑

Express delivery

5–9 days. €27,35

πŸ”’

Crypto discount

βˆ’10% when paying with cryptocurrency.

πŸ”„

Reorder discount

βˆ’10% on all repeat orders.

πŸ“¦ Packaging and discretion

All orders are packed in neutral, unbranded boxes with no product name on the outside.

Iris van Leeuwen
Medically reviewed by
Iris van Leeuwen
General Practitioner (MD)